Mark A Lubkowitz

Title: Mark A Lubkowitz: Innovator in Oligopeptide Transport

Introduction

Mark A Lubkowitz is a notable inventor based in Berkeley, CA (US). He has made significant contributions to the field of molecular biology, particularly in the study of oligopeptide transport mechanisms. His work has implications for antifungal drug targeting, especially against Candida albicans.

Latest Patents

Mark A Lubkowitz holds a patent for the "Isolated Candida albicans oligopeptide transporter gene." This patent describes the cloning of an oligopeptide transport gene, OPT1, from a genomic library. The gene was expressed in a di-/tripeptide transport mutant, PB1X-9B, which allowed for the identification of its transport capabilities. The research demonstrated that when transformed with a plasmid harboring OPT1, PB1X-9B exhibited an oligopeptide transport phenotype. This was evidenced by its growth on specific tetrapeptides and its sensitivity to toxic peptides. The sequencing of the 3.8 kb fragment revealed an open reading frame of 2349 nucleotides, leading to the identification of a protein product with 783 amino acid residues, which is believed to function as a membrane transport protein.

Career Highlights

Mark A Lubkowitz is affiliated with the University of Tennessee Research Foundation, where he continues to advance research in his field. His innovative work has garnered attention for its potential applications in medical science, particularly in developing antifungal therapies.

Collaborations

Mark has collaborated with Jeffrey M Becker, contributing to the advancement of knowledge in oligopeptide transport and its applications.

Conclusion

Mark A Lubkowitz is a distinguished inventor whose work on oligopeptide transport has significant implications for antifungal drug development. His contributions to the field continue to inspire further research and innovation.